BERKELEY, Calif., Nov. 2, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced several presentations that will highlight advances in the company’s biodefense program and particularly in the development of XOMA 3AB, an antibody co-mixture that binds to distinct regions of botulinum toxin type A. The presentations will be made at the Interagency Botulism Research Coordinating Committee Meeting (IBRCC), the largest dedicated meeting of interagency experts in the development of therapies against the botulinum toxin bioterror threat. The IBRCC meeting is taking place from November 2 to 5, 2010 in Atlanta, GA.
